Roots Analysis is pleased to announce the publication of its recent study, titled, “Biopharma Contract Manufacturing Market, 2021-2030.” 

The report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs. Amongst other elements, the report includes:

• A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters.
• Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing, and packaging of biologics.
• A detailed discussion on the key enablers in this domain, including certain niche product classes, which are likely to have a significant impact on the growth of the contract services market.
• A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
• A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
• A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.
• An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics.
• A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity.
• An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.
• An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions.
• A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
• A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.
• A discussion on affiliated trends, key drivers, and challenges, under a comprehensive SWOT framework.
• A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.

Request for Customization: https://www.rootsanalysis.com/reports/250/request-customization.html     ;

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Commonly Outsourced Business Operations

• Active Pharmaceutical Ingredients (API)
• Finished Dosage Formulations (FDF)

Types of Expression System

• Mammalian
• Microbial
• Others

Company Size

• Small
• Mid-Sized
• Large and Very Large

Scale of Operation

• Preclinical
• Clinical
• Commercial

Key Geographical Region

• North America
• Europe
• Asia-Pacific
• Rest of the World

The report also features detailed transcripts of discussions held with the following experts:

• Astrid Brammer, Senior Manager Business Development, Richter-Helm Mathias Schmidt (Chief Executive Officer, ArmaGen)
• Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
• Christian Bailly, Director of CDMO, Pierre Fabre
• Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
• David C Cunningham, Director Corporate Development, Goodwin Biotechnology
• Dietmar Katinger, Chief Executive Officer, Polymun Scientific
• Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma
• Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences
• Kevin Daley, Director Pharmaceuticals, Novasep
• Mark Wright, Site Head, Grangemouth, Piramal Healthcare
• Nicolas Grandchamp, R&D Leader, GEG Tech
• Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals
• Sebastian Schuck, Head of Business Development, Wacker Biotech
• Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
• Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactory
• Tim Oldham, Chief Executive Officer, Cell Therapies

Key companies covered in the report

• 3P Biopharmaceuticals
• Abzena
• Albany Molecular Research
• BioVectra
• BioXcellence (Boehringer Ingelheim)
• Celonic
• Charles River Laboratories
• ChemPartner
• Cobra Biologics
• CordenPharma
• Cytovance Biologics
• GE Healthcare
• Goodwin Biotechnology
• Grand River Aseptic Manufacturing
• IDT Biologika
• KBI BioPharma
• Kemwell Biopharma
• LFB Biomanufacturing
• Meridian Life Science
• Patheon
• Pfizer CentreOne
• PX'Therapeutics
• Samsung BioLogics
• Sanofi, CEPiA
• Thermo Fisher Scientific
• Vetter Pharma International

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/250/request-sample.html    

Also Visit Our Latest Publication:

Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market

CAR-T Cell Therapies Market

Patient Recruitment and Retention Services Market

mRNA Therapeutics and Vaccines Market

T-Cell (CAR-T, TCR, and TIL) Therapies Market

Roots Analysis is pleased to announce the publication of its recent study, titled, “Antibody Contract Manufacturing Market, 2020-2030” report to its list of offerings.

Although biopharmaceuticals offer significant profit margins and have been proven to be effective in treating a myriad of diseases, they are generally associated with high costs of development and complex manufacturing protocols; this is true for antibody-based products as well. Presently, there are a number of companies that claim to offer end-to-end solutions, ranging from antibody development to commercial production.

Read Detailed Analysis: https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html

The report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of antibodies. The study also features a detailed analysis of key drivers and trends related to this evolving domain. In addition to other elements, the study includes:

• A detailed review of the overall landscape of companies, offering contract services for the manufacturing of antibodies.
• A competitiveness analysis of key players engaged in this domain, featuring an assessment based on their supplier strength and service strength.
• A benchmark analysis, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective (geography-based) peer groups.
• An analysis of the various partnerships pertaining to contract manufacturing of antibodies, which have been established since 2013.
• An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective antibody manufacturing capabilities, over the period 2017-2019 (till October).
• An estimate of the overall, installed capacity for manufacturing antibodies based on data reported by industry stakeholders in the public domain.
• Informed estimates of the annual commercial and clinical demand for antibodies, based on various relevant parameters, such as target patient population, dosing frequency and dose strength.
• Elaborate profiles of the key industry players that offer contract manufacturing services at all scales of operation and have more than two manufacturing facilities.
• A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps and challenges involved in their respective manufacturing processes.
• A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution.

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Ask for Customization @ https://www.rootsanalysis.com/reports/295/request-customization.html

Type of Antibodies

• Monoclonal Antibodies
• Bispecific Antibodies
• ADCs
• Others

Company Size

• Small
• Mid-sized
• Large / Very Large

Scale of Operation

• Preclinical / Clinical
• Commercial

Type of expression system used

• Mammalian
• Microbial

Key geographical regions

• North America
• Europe
• Asia and RoW

Transcripts of interviews held with the following senior level representatives of stakeholder companies:

• Dietmar Katinger (Chief Executive Officer, Polymun Scientific)
• David C Cunningham (Director, Corporate Development, Goodwin Biotechnology)
• Claire Otjes (Marketing Manager, Batavia Biosciences)

Market Key Players:

• AGC Biologics
• Aldevron
• AMRI
• Boehringer Ingelheim BioXcellence
• Emergent BioSolutions
• Eurofins CDMO
• FUJIFILM Diosynth Biotechnologies
• KBI Biopharma
• Lonza
• Nitto Avecia Pharma Services
• Novasep
• Pierre Fabre
• Samsung BioLogics
• Synthon
• Thermo Fisher Scientific

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/295/request-sample.html    

Also Visit Our Latest Publication:

Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market

CAR-T Cell Therapies Market

Patient Recruitment and Retention Services Market

mRNA Therapeutics and Vaccines Market

T-Cell (CAR-T, TCR, and TIL) Therapies Market

The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago.

Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.

The USD 3.6 billion (by 2030) financial opportunity within the Target Protein Degradation Market has been analyzed across the following segments:

Type of payment of licensing agreements

• Upfront payments
• Milestone payments

Type of protein degrader

• Degronimids
• PROTACs
• SARDs / SERDs
• Specific BET and DUB inhibitors
• Other protein degraders

Therapeutic area

• Neurodegenerative disorders
• Oncological disorders
• Other therapeutic areas

Route of administration 

• Oral
• Intravenous
• Other routes

Key geographical region

• North America
• Europe
• Asia-Pacific

Get Detailed Analysis: https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

Key Inclusions